Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 1, 2011, Pages 16-22

  Bianchini, Romina M ^a   Castellano, Patricia M ^a   Kaufman, Teodoro S ^a  

^a Universidad Nacional de Rosario   (Argentina)

Author keywords

NMR spectroscopic analysis; Photodegradation; Potential impurities; Structural elucidation; Valsartan

Indexed keywords

ALKENE DERIVATIVE; AMIDE; N (DIAZIRINO[1,3 F]PHENANTHRIDIN 4 YLMETHYL) N ISOBUTYLPENTANAMIDE; N [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] N ISOBUTYLPENTANAMIDE; NITROGEN; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; COLUMN CHROMATOGRAPHY; CYCLIZATION; DECARBOXYLATION; DRUG DEGRADATION; DRUG IMPURITY; DRUG STABILITY; NUCLEAR MAGNETIC RESONANCE; PHOTODEGRADATION; PRIORITY JOURNAL; RADIATION EXPOSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AZIRINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PHENANTHRIDINES; PHOTOLYSIS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TETRAZOLES; VALINE;

EID: 79958045162     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.04.017     Document Type: Article

References (34)

1. Thurmann P.A. Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin. Pharmacother. 2000, 1:337-350.
2. European Pharmacopoeia, 7th ed., Valsartan, Ph. Eur. Monograph 2423, Council of Europe, Strasbourg, France, 2010, pp. 3191-3192.
3. The United States Pharmacopeia, 32th Ed., Valsartan, United States Pharmacopoeial Convention, Inc., Rockville, MD, USA, 2009, p. 3842.
4. Francotte E., Davatz A., Richert P. Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester. J. Chromatogr. B: Biomed. Sci. Appl. 1996, 686:77-83.
5. Rane V., Patil K., Shinde D. Enantiomeric LC separation of valsartan on amylose based stationary phase. Pharmazie 2009, 64:495-498.
6. Sampath A., Raghupathi Reddy A., Yakambaram B., Thirupathi A., Prabhakar M., Pratap Reddy P., Prabhakar Reddy V. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist. J. Pharm. Biomed. Anal. 2009, 50:405-412.
7. Nie J., Xiang B., Feng Y., Wang D. Isolation and identification of process impurities in crude valsartan by HPLC, mass spectrometry, and nuclear magnetic resonance spectroscopy. J. Liq. Chromatogr. Relat. Technol. 2006, 29:553-568.
8. Patro S.K., Kanungo S.K., Patro V.J., Choudhury N.S.K. Stability indicating RP-HPLC method for determination of valsartan in pure and pharmaceutical formulation. E-Journal Chem. 2010, 7:246-252.
9. Capello B., Di Maio C., Iervolino M., Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2006, 54:289-294.
10. Chitlange S.S., Bagri K., Sakarkar D.M. Stability indicating RP-HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation. Asian J. Res. Chem. 2008, 1:15-18.
11. Patel S.B., Chaudhari B.G., Buch M.K., Patel A.B. Stability indicating RP-HPLC method for simultaneous determination of valsartan and amlodipine from their combination drug product. Int. J. ChemTech Res. 2009, 1:1257-1267.
12. Ivanovic D., Malenovic A., Jancic B., Medenica M., Maškovic M. Monitoring of impurity level of valsartan and hydrochlorothiazide employing an RP-HPLC gradient mode. J. Liq. Chromatogr. Relat. Technol. 2007, 30:2879-2890.
13. Krishnaiah Ch., Raghupathi Reddy A., Kumar R., Mukkanti K. Stability-indicating UPLC method for determination of valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J. Pharm. Biomed. Anal. 2010, 53:483-489.
14. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH Q1B, Photostability Testing of New Drug Substances and Products, 1996, pp. 1-8.
15. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH Q1A(R2), Stability Testing of New Drug Substances and Products, 2003, pp. 1-18.
16. Bakshi M., Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 2002, 28:1011-1040.
17. Photostability of Drugs and Drug Formulations 1996, 1-7. Taylor & Francis, London, 65-66. H.H. Tonnesen (Ed.).
18. Sudesh B.M., Uttamrao K.S. Determination and validation of valsartan and its degradation products by isocratic HPLC. J. Chem. Metrol. 2009, 3:1-12.
19. Shrivastava A.R., Barhate C.R., Kapadia C.J. Stress degradation studies on valsartan using validated stability-indicating high-performance thin-layer chromatography. J. Planar Chromatogr. 2009, 22:411-416.
20. Agrahari V., Kabra V., Gupta S., Kumar Nema R., Nagar M., Karthikeyan C., Trivedi P. Determination of inherent stability of valsartan by stress degradation and its validation by HPLC. Int. J. Pharm. Clin. Res. 2009, 1:77-81.
21. Rao K.S., Jena N., Rao M.E.B. Development and validation of a specific stability indicating high performance liquid chromatographic method for valsartan. J. Young Pharm. 2010, 2:183-189.
22. Lakshmi K.S., Sivasubramanian L. A stability indicating HPLC method for the simultaneous determination of valsartan and ramipril in binary combination. J. Chil. Chem. Soc. 2010, 55:223-226.
23. Mehta S., Shah R.P., Singh S. Strategy for identification and characterization of small quantities of drug degradation products using LC and LC-MS: application to valsartan, a model drug, Drug Test. Anal. 2010, 2:82-90.
24. Chen S.-M., Hsieh M.-C., Chao S.-H., Chang E.E., Wang P.-Y., Wu A.-B. Separation and structure determination of nicardipine photoproducts by LC-ESI-MS. Biomed. Chromatogr. 2008, 22:1008-1012.
25. Light sources and filters. Handbook of Photochemistry 2006, 583-585. CRC Press, Boca Raton, FL. 3rd ed. M. Montalti, A. Credi, L. Prodi, M.T. Gandolfi (Eds.).
26. Li F., Zhang H., Jiang L., Zhang W., Nie J., Feng Y., Yang M., Liu M. Dynamic NMR study and theoretical calculations on the conformational exchange of valsartan and related compounds. Magn. Reson. Chem. 2007, 45:929-936.
27. Billes F., Endrédi H., Keresztury G. Vibrational spectroscopy of triazoles and tetrazole. J. Mol. Struct. 2000, 530:183-200.
28. Marek R., Lycka A. 15N NMR spectroscopy in structural analysis. Curr. Org. Chem. 2002, 6:35-66.
29. Breier A.R., Nudelman N.S., Steppe M., Schapoval E.E.S. Isolation and structure elucidation of photodegradation products of fexofenadine. J. Pharm. Biomed. Anal. 2008, 46:250-257.
30. Packer J.L., Werner J.J., Latch D.E., McNeill K., Arnold W.A. Photochemical fate of pharmaceuticals in the environment: naproxen, diclofenac, clofibric acid, and ibuprofen. Aquat. Sci. 2003, 65:342-351.
31. Mehta S., Shah R.P., Priyadarshi R., Singh S. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil. J. Pharm. Biomed. Anal. 2010, 52:345-354.
32. Shah R.P., Sahu A., Singh S. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MSn, on-line H/D exchange and LC-NMR. J. Pharm. Biomed. Anal. 2010, 51:1037-1046.
33. Shah R.P., Singh S. Identification and characterization of a photolytic degradation product of telmisartan using LC-MS/TOF, LC-MSn, LC-NMR and on-line H/D exchange mass studies. J. Pharm. Biomed. Anal. 2010, 53:755-761.
34. Hyatt J.A., Swenton J.S. Photochemistry in the tetrazole-azidoazomethine system A facile synthesis of 9H-pyrimido[4,5-b]indoles,. J. Org. Chem. 1972, 37:3216-3220.